$PFSA

HRT FINANCIAL LP sold $1K of PFSA

HRT FINANCIAL LP sold 1,307 shares of Profusa, Inc. (PFSA) at an average of $0.94 ($0.94–$0.95) across 2 trades over 2026-08-05 to 2026-08-07.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Aug 10, 2026, 7:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 7:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFSA
Neutral
medium confidence
Mentioned
$PFSA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFSANeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale size, price range, and post-transaction holdings. However, there is no accompanying fundamental update (earnings, guidance, trial results, or corporate action) in the text provided.

02

Market read

Traders may note insider selling as a mild sentiment input, but the disclosed transaction value ($1,234.89) is unlikely to be a standalone driver.

03

What to watch

The article does not state whether the holder’s remaining stake is changing meaningfully over time, nor does it provide context on prior sales or total position size changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-10 for sales executed 2026-08-05 to 2026-08-07

Background

The filing is an SEC Form 4 insider transaction report for Profusa, Inc. (PFSA), reported by HRT Financial LP as a 10% owner.

Company-level read

Ticker impact

$PFSANeutralMedium confidence
Context

HRT Financial LP, a 10% owner of Profusa, sold 1,307 PFSA shares in open-market transactions at about $0.9448 weighted average.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 shows an open-market sale by a large holder, but the article provides no new company-specific catalyst, guidance, or regulatory/legal development.

Market effects

No sector read-through beyond routine insider activity in a microcap/early-stage biotech context.

None indicated.

None indicated.

Counterpoint

The sale could be liquidity management or diversification rather than a bearish view, especially since it is not tied to a 10b5-1 plan in the filing.

Key entities

  • Profusa, Inc.

    Public company whose shares (PFSA) were sold by a 10% owner via open-market transactions.

  • HRT Financial LP

    10% owner that sold 1,307 shares of PFSA at an average price of about $0.9448.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFSALow

Profusa, Inc. (PFSA): Results of Operations and Financial Condition

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.